|
|
Post by halmorris on Mar 29, 2019 2:23:47 GMT -5
CEL-SCI Corporation CVM, +7.02% believes that boosting a patient's immune system while it is still intact should provide the greatest possible impact on survival. CEL-SCI Corporation recently reported its financial results for the quarter ended December 31, 2018. CEL-SCI's Phase 3 head and neck cancer study continued to follow all 928 patients who were enrolled. The Company is now awaiting final study results. All that remains to be done in this pivotal Phase 3 study, the largest in the world in head and neck cancer, is to continue to track patient survival until it can be determined if the primary endpoint has been met. The primary endpoint of the study, a 10% improvement in overall survival of the Multikine* treatment regimen plus Standard of Care (SOC) vs. SOC alone, will be determined after a total of 298 events have occurred in the two main comparator arms of the study and have been recorded in the study database. These final results could come soon since the last patients were treated in September 2016. The U.S. Patent and Trademark Office issued two new patents for CEL-SCI's LEAPS platform technology. The inventions relate to methods for diagnosing, preventing, and treating disease by generating or modulating immune response through the use of specific peptides. During the first quarter, CEL-SCI's LEAPS platform technology continued its development program as a therapeutic vaccine for rheumatoid arthritis under a USD 1.5 Million grant from the U.S. National Institutes of Health (NIH). Between January 1, 2019 and February 13, 2019, the Company received approximately USD 2.1 Million through the exercise of warrants to purchase shares of the Company's common stock. "During the first quarter of fiscal 2019, we continued to follow patients in our Phase 3 head and neck cancer trial, as we await a readout of topline results from this pivotal study, which may result in the first new approved first-line therapy for advanced primary (not yet treated) head and neck cancer in over 60 years. Concurrently, we continue to advance our LEAPS platform through studies with the NIH while fortifying our intellectual property around this unique vaccine technology," stated CEL-SCI Chief Executive Officer, Geert Kersten.
|
|
|
|
Post by halmorris on Apr 8, 2019 15:43:56 GMT -5
Now up to $6.13 after close Today
|
|
|
|
Post by halmorris on May 7, 2019 15:47:54 GMT -5
Now up to $7.24 after close Today
|
|
|
|
Post by halmorris on May 10, 2019 16:53:04 GMT -5
$8.05 after Close Today, They are in Phase 3 and it looks great for FDA approval and then Buy Out or the Stock goes to $50 - $100, This is a Cancer Phase 3 Drug Multikine, the Employees are taking Stock as Pay for the Last 2 Months.
|
|
|
|
Post by halmorris on Jun 10, 2019 16:00:46 GMT -5
|
|
|
|
Post by halmorris on Jun 24, 2019 16:43:46 GMT -5
$8.74 at Close Today and still time to get in, this was once a $430 Stock, Head and Neck Cancer in Phase 3, The CRO has put in $12 Million, if Phase 3 Successful this is a $50 - $250 Stock !!!
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jun 24, 2019 18:32:47 GMT -5
And that's why I can't buy biotech. For every one that I've seen explode upward on an approval, I've seen ten lose 50-90% of their value on a miss.
Fun to speculate on, but (personally), I wouldn't ever commit enough money to make it matter if I was right. I think that's why you don't see many on the Forbes 400 that claim "biotech" as their source of wealth.
I heard that sentiment from the guy that founded Intrexon (XON), Randall Kirk. He's done well in the area, but one time I heard him asked why he didn't think more from the biotech industry was on that list and his comment was along the lines of "because not that many are willing to put it all on the line for something that could go to zero".
BUT, I would LOVE to understand it and be able to place some bets there. I try to watch what Julian and Felix Baker (i.e..the Baker Brothers) are doing in order to keep up with things. They've been pretty darn good at it over the years. I did toy with Kite, Juno, and Bluebird a few years ago. Did ok but nothing to change my way of life. 
Just didn't want you to think nobody was watching your post Hal. I'm just a dead atheist when it comes to this area. You do know what the dead atheist is don't you? All dressed up and nowhere to go! |
|
|
|
Post by halmorris on Jul 15, 2019 22:17:12 GMT -5
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jul 16, 2019 6:06:26 GMT -5
|
|
|
|
Post by halmorris on Aug 13, 2019 16:19:53 GMT -5
$8.74 at Close Today
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Aug 13, 2019 16:28:21 GMT -5
Hal, have you been listening to any of the "digital biotech" guys? I like the companies that are providing services/platforms TO the biotechs and pharma's as opposed to the guys that are actually delivering a product. Sooooo, much going on in this field. Feels like the whole industry is about to take a giant leap forward doesn't it?
But, you were on CVM early no doubt!! Stock closed at $3.54 the day you first posted it! Great call! A double in a little over 4 months "ain't bad"!!
These things can be like lottery tickets. It could quadruple on good news.
See Deciphera Pharmaceuticals Inc (DCPH) today? Up around 100% at one time...took Blueprint Medicine (BPMC) down...I looked at that one but passed. The right results and bingo.....but.....the wrong results and its painful. See many drugs miss and the companies practically vanish overnight.
Another high stakes games! |
|
|
|
Post by halmorris on Sept 17, 2019 5:13:11 GMT -5
$9.18 at Close Today and a Conference Call coming up
|
|
|
|
Post by halmorris on Sept 26, 2019 17:08:59 GMT -5
$9.55 at Close, Here comes $10
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 27, 2019 16:05:38 GMT -5
Hal, do you realize your recommendation has dusted LVS?
If, on the day you first posted this stock......March the 29th, had you put 10k into LVS, you would have been able to buy 165 shares at $60.33 (just using the closing price), and you would have been able to buy 3,125 shares of CVM at $3.20 (again, just using the closing price).
Today?
LVS would be worth $9,423 and CVM would be worth $28,125
Whew! If there were ever a case for "I'd rather be rich than right", this would be a good argument. You could have everybody agreeing why LVS was such a good buy (bridge, Japan, dividend yada yada yada), but in the end.....they would have rather owned CVM!! LVS's dividend won't cover underperformance to that degree.
|
|
|
|
Post by Blitz on Sept 27, 2019 22:32:06 GMT -5
That’s why this section is in our forum.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Sept 28, 2019 5:47:17 GMT -5
That’s why this section is in our forum. And why I hang around/check in even though I haven't had any gaming interest since the CZR/ERI deal was announced. |
|
|
|
Post by halmorris on Dec 18, 2019 18:31:54 GMT -5
$9.24 at Close Today !!!
|
|
|
|
Post by halmorris on Jan 16, 2020 17:24:14 GMT -5
|
|
|
|
Post by halmorris on Jan 21, 2020 18:32:05 GMT -5
$12.65 at Close Today
|
|
|
|
Post by halmorris on Jan 22, 2020 16:25:53 GMT -5
$13.59 at Close Today, Maybe a little pullback but I don't know
|
|
|
|
Post by halmorris on Feb 3, 2020 16:22:46 GMT -5
$14.34 at Close Today
|
|
|
|
Post by halmorris on Feb 19, 2020 20:16:51 GMT -5
$16.20 @ Close Today
|
|
|
|
Post by Blitz on Feb 20, 2020 7:28:31 GMT -5
CEL-SCI Corporation (NYSE American: CVM) today reported financial results for the quarter ended December 31, 2019. cel-sci.com/news-events/In October 2019, the Independent Data Monitoring Committee (IDMC) for the Company's pivotal Phase 3 head and neck cancer study of its investigational immunotherapy Multikine* (Leukocyte Interleukin, Injection) performed an official review of the study data and recommended that the trial continue until the appropriate number of events has occurred. The data from all 928 enrolled patients were provided to the IDMC by the clinical research organization (CRO) responsible for data management of this Phase 3 study. The IDMC reviewed “progression free and overall survival and limited demographic and safety data available for the aforementioned protocol.” The Company is now awaiting final study results for the Phase 3 trial, which is the largest study in the world in head and neck cancer. All that remains to be done is to continue to track patient survival until the required number of events have occurred and all of the data have been reviewed and recorded in the study database to allow a determination to be made if the primary endpoint has been met. The primary endpoint of the study is a 10% improvement in overall survival of the Multikine treatment regimen plus standard of care (SOC) vs. SOC alone, the two main comparator arms of the study. “Our study has now been running for 9 years with the last patients being enrolled in September 2016. We believe that the delay in reaching 298 events is a good sign for the study because patients appear to be living longer than was expected when the study was planned. However, we would be surprised if the study did not end soon. Since the study is well controlled and the SEER data base shows no improvement in the survival of patients treated with standard of care since the study began, it seems illogical that the patients living longer than expected would be patients receiving the standard of care therapies only. We are therefore preparing for commercial scale production of Multikine at our manufacturing facility,” stated CEL-SCI CEO, Geert Kersten. Here's a very detailed version of the potential and risks: s1.q4cdn.com/460208960/files/News/2019/Zacks_SCR_Research_01312019_CVM_Vandermosten.pdf |
|
|
|
Post by halmorris on Feb 20, 2020 17:40:14 GMT -5
$17.05 @ Close Today..Still Time to get in, This will be $30 - $100 on approval +
|
|
|
|
Post by halmorris on Mar 9, 2020 22:32:25 GMT -5
This went to $22 PRE MARKET 3/9/2020 and then dropped back down, they are now working on Corona Virus with their Leaps Therapy.
|
|
